Andere talen Exact Sciences Corporation

Aandelen

EXAS

US30063P1057

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
63,48 ^USD	+0,41%		-12,98%	-14,19%

15/04	Exact Sciences Corporation kondigt wijzigingen in de leiding aan	CI
11/04	Exact Sciences tekent schuldruilovereenkomst, plaatsing van converteerbare obligaties	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Exact Sciences Corporation announced that it has received $266.75 million in funding	17/04
Sector Update: Health Care Stocks Advance Premarket Monday	15/04
Exact Sciences Names Aaron Bloomer CFO	15/04
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer	15/04
Exact Sciences Appoints Aaron Bloomer as Chief Financial Officer, Effective from May 15, 2024	15/04
Exact Sciences Corporation Announces Executive Changes	15/04
Exact Sciences Signs Debt Exchange Deal, Placement of Convertible Notes	11/04
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes	11/04
Exact Sciences Corporation announced that it expects to receive $266.8 million in funding	10/04
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024	08/04
Exact Sciences Schedules First Quarter 2024 Earnings Call	08/04
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment	04/04
Maverix Medical Closes Acquisition of Cirrus Bio as Foundation for Diagnostics Platform in Lung Cancer	01/04
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer	28/03
Exact Sciences Corp. Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer	28/03
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner	27/03
The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study	13/03
Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer	07/03
Exact Sciences Insider Sold Shares Worth $287,500, According to a Recent SEC Filing	05/03
EXACT SCIENCES LAUNCHES RISKGUARD HEREDITARY CANCER TEST IN THE UNITED STATES	29/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Exact Sciences Corporation

Aandelen

EXAS

US30063P1057

Andere talen

Filters